Labcorp launches blood test for neurodegenerative diseases detection

“Global life sciences company Labcorp has announced the first commercially available glial fibrillary acidic protein (GFAP) blood biomarker test in the US, offering a new tool for the early detection of neurodegenerative diseases and brain injuries. The new tool measures GFAP, an early-stage indicator of neurological damage, from a simple blood draw using highly sensitive immunoassay technology. Now part of Labcorp’s extensive neurology portfolio, the test represents a significant advancement in the diagnosis and management of neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, glioblastoma, and traumatic brain injury (TBI).”  This is a commercial statement, not implying MAIN’s endorsement.  We can, however, recommend Dr. Thomas E. Powell, III and Daniel Ayers’ 2023 history of Labcorp, Equity: Biomedical Reference Laboratories (Thomas E. Powell Company, 2010 S. Church Street, Burlington, NC 27215; $34.95).     MORE

Image Credit: Medical Devices Network